Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
A total of six presentations will highlight the unique attributes of CD101, Cidara’s lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class. Specifically, data to be presented will showcase the potential advantages of CD101, which has exhibited the following characteristics: in vivo activity against emerging resistant organisms; high target-attainment and exposure to treat less susceptible pathogens; superior tissue penetration compared to micafungin; and biofilm activity.
“These presentations reflect our comprehensive program to build the foundation of a superior antifungal profile for CD101,” said
Details of the Cidara IDWeek and TIMM presentations are as follows:
IDWeek 2017 Presentations
- 1518: Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis; C. Hager, et. al.
- 1528: In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model;
A. J. Lepak, et. al.
- 1533: Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model; Y. Zhao, et. al.
2017 TIMM Presentations
- P057: Evaluate the Ability of CD101 to Prevent and Treat Candida albicans Biofilms and Explore its Temporal Effect by Time Lapse Photography; J. Chandra, et. al.
- P349: PK/PD Target Characterization of the Novel Echinocandin CD101 Against Candida spp. in a Neutropenic Mouse Model of Disseminated Candidiasis;
A. J. Lepak, et. al.
- S15.2 (
2:27 p.m.): CD101; T. Sandison
Copies of these posters and presentations will be available on the Cidara website following the meetings: http://www.Cidara.com/
About Fungal Infections
Approximately 97,000 Americans die from hospital-related fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. The emergence of a new and virulent fungal pathogen called Candida auris (C. auris) is also an emerging public health threat due to its resistance to existing antifungal agents. As of
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential advantages, effectiveness, safety, and other attributes of CD101 and other potential product candidates, including the potential for these compounds to successfully treat or prevent infections, including those caused by resistant pathogens, and potentially transform the way infectious diseases are treated, and the potential for the Cloudbreak platform to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
Westwicke Partners, LLC